Related Experiment Video
Updated: Mar 12, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
Liver function indicators as risk factors of pediatric metabolic (dysfunction)-associated fatty liver disease: a
Xiaojiao Fan1, Fang Cheng1,2, Hongyun Zhou1
1Department of Pediatrics, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Background:
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is the most common chronic liver disorder in children and adolescents, with its prevalence rising alongside the global childhood obesity epidemic. Liver function indicators offer a potential non-invasive screening alternative, but existing evidence on their association with pediatric MAFLD is inconsistent due to heterogeneous study designs and populations. Therefore, this systematic review and meta-analysis aimed to synthesize global evidence to definitively evaluate liver function indicators as risk factors for MAFLD in children and adolescents.
Methods:
Four databases-The Cochrane Library, Embase, Web of Science, and PubMed-were searched from inception to July 5, 2025. The eligible studies were observational in design and focused on children and adolescents (<18 years), comparing MAFLD prevalence/risk between those with abnormal versus normal liver function indicators. Two independent researchers performed literature screening, information collection, and quality evaluation per the eligibility criteria. The 'meta' package in R was adopted to compute the odds ratio (OR) and corresponding 95% confidence interval (CI) for the association between liver function indicators and MAFLD. Heterogeneity and publication bias were also assessed.
Results:
This meta-analysis incorporated 27 studies, involving 3,237 confirmed MAFLD cases. Levels of alanine aminotransferase (ALT) [OR (95% CI): 1.15 (1.01, 1.30)], gamma-glutamyl transferase (GGT) [1.30 (1.09, 1.56)], and high-density lipoprotein (HDL) [0.97 (0.96, 0.98)] were associated with MAFLD risk. Elevated ALT [OR (95% CI): 20.63 (2.39, 178.09)], total cholesterol (TC) [3.36 (1.15, 9.82)], triglycerides (TG) [4.86 (2.37, 9.98)], low-density lipoprotein (LDL) [3.74 (1.15, 12.19)], and decreased HDL [2.77 (1.97, 3.91)] were identified as potential risk factors for MAFLD in children and adolescents. Overall, subgroup analyses (by confounder adjustment status and study design), sensitivity analyses, and meta-regression did not identify potential sources of heterogeneity. No significant publication bias was observed.
Conclusions:
Liver function indicators show promise as screening tools for the early detection of MAFLD susceptibility. This study has several limitations, including a small number of included studies, resulting in heterogeneity, as well as the inherent risk of bias (ROB) in observational designs and the imprecision of some results.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Inborn Errors of Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...

